Breaking: Dexcom (NASDAQ:DXCM) “Buy” Rating Maintained by Analysts at BMO Capital Today; The TP is Set to $74.0

April 1, 2018 - By Henry Gaston

DexCom, Inc. (NASDAQ:DXCM) Logo

Investors sentiment decreased to 0.73 in 2017 Q4. Its down 0.24, from 0.97 in 2017Q3. It dropped, as 44 investors sold DexCom, Inc. shares while 97 reduced holdings. 48 funds opened positions while 55 raised stakes. 99.11 million shares or 0.83% more from 98.30 million shares in 2017Q3 were reported.

Soros Fund Mngmt Limited Liability Corp invested in 3,800 shares. 200 are owned by Rech &. Granahan Inv Management Ma reported 25,835 shares stake. Qs Ltd Llc reported 2,907 shares or 0% of all its holdings. Sterling Lc invested 0.01% in DexCom, Inc. (NASDAQ:DXCM). Sei Invs holds 0.02% or 102,798 shares in its portfolio. Macquarie Group reported 188,177 shares. Utah Retirement Sys has 15,900 shares. Rosenblum Silverman Sutton S F Ca reported 0.6% in DexCom, Inc. (NASDAQ:DXCM). Lpl Ltd Liability Company reported 0% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Invesco Ltd reported 1.28 million shares. State Board Of Administration Of Florida Retirement Sys has invested 0.02% in DexCom, Inc. (NASDAQ:DXCM). Franklin Resource Incorporated has 1.17 million shares. Bnp Paribas Arbitrage invested 0% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Schroder Inv Management has 0.08% invested in DexCom, Inc. (NASDAQ:DXCM) for 833,752 shares.

Since October 23, 2017, it had 0 insider purchases, and 8 selling transactions for $2.59 million activity. Shares for $198,691 were sold by Balo Andrew K. SAYER KEVIN R sold $353,092 worth of stock or 6,000 shares. GREGG TERRANCE H sold 10,000 shares worth $559,095.

Dexcom (NASDAQ:DXCM) Rating Reaffirmed

Recently, In analysts note issued to clients on Tuesday, 12 December, Dexcom (NASDAQ:DXCM) shares have had their “Buy” Rating reconfirmed by stock research analysts at BMO Capital, who currently has a $74.0 PT on company. This target by BMO Capital means the possibile downside of -0.22 % from the previous stock close.

Investors sentiment decreased to 0.73 in 2017 Q4. Its down 0.24, from 0.97 in 2017Q3. It dropped, as 44 investors sold DexCom, Inc. shares while 97 reduced holdings. 48 funds opened positions while 55 raised stakes. 99.11 million shares or 0.83% more from 98.30 million shares in 2017Q3 were reported.

Soros Fund Mngmt Limited Liability Corp invested in 3,800 shares. 200 are owned by Rech &. Granahan Inv Management Ma reported 25,835 shares stake. Qs Ltd Llc reported 2,907 shares or 0% of all its holdings. Sterling Lc invested 0.01% in DexCom, Inc. (NASDAQ:DXCM). Sei Invs holds 0.02% or 102,798 shares in its portfolio. Macquarie Group reported 188,177 shares. Utah Retirement Sys has 15,900 shares. Rosenblum Silverman Sutton S F Ca reported 0.6% in DexCom, Inc. (NASDAQ:DXCM). Lpl Ltd Liability Company reported 0% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Invesco Ltd reported 1.28 million shares. State Board Of Administration Of Florida Retirement Sys has invested 0.02% in DexCom, Inc. (NASDAQ:DXCM). Franklin Resource Incorporated has 1.17 million shares. Bnp Paribas Arbitrage invested 0% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Schroder Inv Management has 0.08% invested in DexCom, Inc. (NASDAQ:DXCM) for 833,752 shares.

Since October 23, 2017, it had 0 insider purchases, and 8 selling transactions for $2.59 million activity. Shares for $198,691 were sold by Balo Andrew K. SAYER KEVIN R sold $353,092 worth of stock or 6,000 shares. GREGG TERRANCE H sold 10,000 shares worth $559,095.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Among 11 analysts covering Dexcom (NASDAQ:DXCM), 8 have Buy rating, 1 Sell and 2 Hold. Therefore 73% are positive. Dexcom has $7800 highest and $52 lowest target. $69.73’s average target is -5.97% below currents $74.16 stock price. Dexcom had 17 analyst reports since October 4, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, March 28 by Cowen & Co. The stock has “Buy” rating by Oppenheimer on Monday, February 12. As per Friday, March 23, the company rating was maintained by Piper Jaffray. As per Wednesday, February 28, the company rating was maintained by Canaccord Genuity. The stock has “Buy” rating by Canaccord Genuity on Wednesday, March 28. The stock of DexCom, Inc. (NASDAQ:DXCM) has “Buy” rating given on Wednesday, October 4 by Wedbush. Robert W. Baird upgraded the shares of DXCM in report on Friday, March 23 to “Outperform” rating. As per Wednesday, January 17, the company rating was maintained by BMO Capital Markets. The firm has “Equal-Weight” rating by Barclays Capital given on Thursday, November 2. Jefferies maintained it with “Buy” rating and $70.0 target in Thursday, December 21 report.

The stock increased 1.20% or $0.88 during the last trading session, reaching $74.16. About 1.80 million shares traded or 39.55% up from the average. DexCom, Inc. (NASDAQ:DXCM) has declined 16.08% since April 1, 2017 and is downtrending. It has underperformed by 27.63% the S&P500.

Analysts await DexCom, Inc. (NASDAQ:DXCM) to report earnings on May, 1. They expect $-0.32 earnings per share, up 34.69 % or $0.17 from last year’s $-0.49 per share. After $0.10 actual earnings per share reported by DexCom, Inc. for the previous quarter, Wall Street now forecasts -420.00 % negative EPS growth.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $6.45 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. It currently has negative earnings. The Company’s products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patientÂ’s mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management.

DexCom, Inc. (NASDAQ:DXCM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.